Rapid Influenza Diagnostics companies

  • Report ID: 5310
  • Published Date: May 09, 2025
  • Report Format: PDF, PPT

Key Rapid Influenza Diagnostics Market Players:

    As the rapid influenza diagnostics market is growing steadily, the main competitors, such as Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Quidel Corporation, are focusing on innovation and product development. Besides, Abbott’s ID NOW Influenza A & B 2 test provides quick results at the point of care to meet the demand for rapid diagnosis, which is positively impacting the overall market globally. Moreover, as companies compete to improve accuracy, speed, and accessibility, they are adjusting to the growing global demand, which further denotes a huge growth opportunity for the market across different nations.

    Here is a list of key players operating in the global market: 

    • Abbott Laboratories
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd
    • Quidel Corporation
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company (BD)
    • Meridian Bioscience Inc.
    • DiaSorin S.p.A.
    • Sekisui Diagnostics LLC
    • Siemens Healthineers AG
    • Danaher Corporation
    • Luminex Corporation
    • bioMérieux SA
    • Hologic Inc.
    • Abbott Laboratories
    • Seegene Inc.

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of the rapid influenza diagnostics market was valued at USD 1.5 billion.

The market size for the rapid influenza diagnostics market is projected to reach USD 2.9 billion by the end of 2035, expanding at a CAGR of approximately 8.7% during the forecast period, i.e., between 2026–2035.

The major players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Quidel Corporation, Thermo Fisher Scientific Inc., and others.

In terms of technology, the lateral flow immunoassays subsegment is anticipated to garner the largest market share of 43% by 2035 and exhibit substantial growth opportunities during 2026–2035.

The market in North America is projected to hold the largest market share of 37% by the end of 2035 and offer substantial business opportunities in the coming years.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos